tetano
Editor, Senior Moderator
SAGE Open Med Case Rep
. 2022 Jan 8;10:2050313X211066646.
doi: 10.1177/2050313X211066646. eCollection 2022.
The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection
Salih Ahmeti[SUP] 1 2 [/SUP], Violeta Lokaj-Berisha[SUP] 3 [/SUP], Besa Gacaferri Lumezi[SUP] 3 [/SUP]
Affiliations
Abstract
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), no specific antiviral drug has been proven effective for the treatment of patients with severe complications. However, a nucleoside prodrug remdesivir (GS-5734) was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19. Preclinical data in animal models of coronavirus diseases have demonstrated that early treatment with remdesivir leads to improved survival and decreased lung injury. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of shorter recovery period and higher odds of improved clinical status in patients with COVID-19. Here, the story of a 79-year-old patient, with 11-year-old left hemiparesis, concomitant cardiovascular disease, infected with SARS-CoV-2, and the clinical improvement after administration of remdesivir during his second hospitalization period is reported.
Keywords: COVID-19; Infectious disease; comorbidity; remdesivir; respiratory medicine.
. 2022 Jan 8;10:2050313X211066646.
doi: 10.1177/2050313X211066646. eCollection 2022.
The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection
Salih Ahmeti[SUP] 1 2 [/SUP], Violeta Lokaj-Berisha[SUP] 3 [/SUP], Besa Gacaferri Lumezi[SUP] 3 [/SUP]
Affiliations
- PMID: 35035971
- PMCID: PMC8753226
- DOI: 10.1177/2050313X211066646
Abstract
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), no specific antiviral drug has been proven effective for the treatment of patients with severe complications. However, a nucleoside prodrug remdesivir (GS-5734) was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19. Preclinical data in animal models of coronavirus diseases have demonstrated that early treatment with remdesivir leads to improved survival and decreased lung injury. Recent clinical data have demonstrated the clinical activity of remdesivir in terms of shorter recovery period and higher odds of improved clinical status in patients with COVID-19. Here, the story of a 79-year-old patient, with 11-year-old left hemiparesis, concomitant cardiovascular disease, infected with SARS-CoV-2, and the clinical improvement after administration of remdesivir during his second hospitalization period is reported.
Keywords: COVID-19; Infectious disease; comorbidity; remdesivir; respiratory medicine.